Circulating CTRP9 independently protected against coronary artery calcification (OR 0.156; 95% CI 0.11-0.21; p<0.05), and combining it with aortic valve calcification improved severe CAC prediction.
Cross-Sectional (n=900)
Do circulating CTRP9 levels and aortic valve calcification jointly predict coronary artery calcification severity in patients with coronary heart disease?
Lower circulating CTRP9 levels are associated with advanced aortic valve calcification and greater coronary artery calcification severity, and combining CTRP9 with AVC enhances risk prediction for severe CAC.
Effect estimate: OR 0.156 (95% CI 0.11-0.21)
p-value: p=<0.05
Background Vascular calcification predicts adverse cardiovascular outcomes. CTRP9, an adiponectin paralog, has vascular protective effects. We evaluated the association of circulating CTRP9 with aortic valve calcification (AVC) and coronary artery calcification (CAC) in a cross-sectional observational study. Methods Nine hundred coronary heart disease patients underwent echocardiography and optical coherence tomography; serum CTRP9 was measured in a subset. Logistic regression identified CAC determinants. ROC analysis assessed CTRP9 alone and combined with AVC for predicting severe CAC. AVC was modeled in ApoE−/− mice fed a Western diet for 24 weeks, with calcification markers analyzed via PCR and Western blot. Results CTRP9 independently protected against CAC (OR = 0.156, 95% CI: 0.11–0.21, p 0.05). CTRP9 predicted CAC severity (AUC = 0.74), and combining it with AVC improved prediction of severe CAC (AUC = 0.843). Kendall’s Tau-b indicated strong correlation between severe AVC and CAC (τb = 0.597, p 0.001). Exogenous CTRP9 attenuated aortic valve calcification in mice. Conclusion Lower CTRP9 levels associate with advanced AVC and greater CAC severity. Combining CTRP9 with AVC enhances risk prediction, highlighting CTRP9 as a potential biomarker and therapeutic target in vascular calcification.
Duan et al. (Wed,) conducted a cross-sectional in Coronary heart disease (n=900). Circulating CTRP9 was evaluated on Coronary artery calcification (OR 0.156, 95% CI 0.11-0.21, p=<0.05). Circulating CTRP9 independently protected against coronary artery calcification (OR 0.156; 95% CI 0.11-0.21; p<0.05), and combining it with aortic valve calcification improved severe CAC prediction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: